Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Merck KGAA, Pfizer, and Syndax enter ovarian cancer trial collaboration

Executive Summary

Merck KGAA, Pfizer Inc., and Syndax Pharmaceuticals Inc. entered into an agreement to explore a combination of the anticancer therapies avelumab and entinostat for patients with heavily pre-treated recurrent ovarian cancer.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Trial Collaborations

Related Companies

Advertisement
UsernamePublicRestriction

Register